![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Genaera Reaches Target Enrollment in Two Phase II Studies for Squalamine
Genaera Reaches Target Enrollment in Two Phase II Studies for Squalamine
Genaera has reached the target enrollment for two of three Phase II studies in "wet" age-related macular degeneration (AMD).
The company enrolled 45 patients in a multicenter, randomized, masked, controlled, U.S. Phase II clinical trial (MSI-1256F-208) with squalamine for the treatment of choroidal neovascularization associated with AMD.
The company also announced that it had completed enrollment in a multicenter, open-label U.S. pharmacokinetics and safety Phase II clinical trial (MSI-1256F-207). Squalamine is the leading systemically delivered anti-angiogenic drug being developed to treat AMD. Enrollment in the MSI-1256F-208 trial will continue through February 2005 in order to accept patients still in screening.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
11Jul
-
18Jul
-
21Oct